Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA

Postagens

Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study

agosto 29, 2016

Lancet. http://ac.els-cdn.com/S014067361630592X/1-s2.0-S014067361630592X-main.pdf?_tid=2bbaab8c-6e22-11e6-91af-00000aacb361&acdnat=1472500552_267c801b1a8103d3afee87b33e288d1c 2016 Jul 26. pii: S0140-6736(16)30592-X. doi: 10.1016/S0140-6736(16)30592-X. [Epub ahead of print] Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Yaxley JW 1 , Coughlin GD 1 , Chambers SK 2 , Occhipinti S 3 , Samaratunga H 4 , Zajdlewicz L 5 , Dunglison N 1 , Carter R 6 , Williams S 7 , Payton DJ 8 , Perry-Keene J 8 , Lavin MF 9 , Gardiner RA 10 . Author information Abstract BACKGROUND: The absence of trial data comparing robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy is a crucial knowledge gap in uro-oncology. We aimed to compare these two approaches in terms of functional and oncological outcomes and report the early postoperative outcomes

Leia mais

Nivolumab Results in High Rate of Response in Refractory Classical Hodgkin's Lymphoma

agosto 29, 2016

· in this single-arm, phase II study, the authors evaluated the efficacy and safety of nivolumab monotherapy in 80 adults with recurrent classical Hodgkin's lymphoma following failure of autologous stem-cell transplantation and brentuximab vedotin. After a median of 8.9 months of follow-up, 66.3% of patients achieved an IRRC-assessed objective response. Common adverse effects included fatigue (25%), reaction to the infusion (20%), and rash (16%). The most common grade ≥3 adverse events were neutropenia (5%) and increased lipase concentrations (5%). There were 3 deaths during the study period but none was thought to be related to therapy. Treatment with nivolumab results in a response in the majority of patients with refractory Hodgkin's lymphoma, and the safety profile is acceptable. Nivolumab may represent a novel treatment option for this population. Hodgkin’s lymphoma is highly curable with chemotherapy